UNOGRANI
GRANISETRON HYROCHLORIDE
What it does
Granisetron is a medication used to prevent nausea and vomiting.
Commonly used for: nausea and vomiting after chemotherapy, nausea and vomiting after surgery
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.
Sourcing - Kenya onlyRegistration & product details
Source: Medicines Control Authority of Zimbabwe · fetched 2026-04-18 08:22:11 · updated 2026-10-18 04:30:12
About granisetron
Granisetron is a medication used to prevent nausea and vomiting.
What it treats
- nausea and vomiting after chemotherapy
- nausea and vomiting after surgery
How it works
Granisetron blocks signals in the brain that trigger nausea and vomiting.
Who it's for
It is for adults and children who are experiencing nausea and vomiting due to medical treatments or surgery.
Cautions
- • Be careful if you are taking other medications that can cause serotonin syndrome, a serious condition that affects the brain.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
About hyrochloride
Hydrochloride is a type of medication often used to treat various conditions, but specific details on its class, interactions, and cautions are not provided.
How it works
Hydrochloride works by affecting certain chemical processes in the body to help manage symptoms or conditions.
Who it's for
This medication may be prescribed to patients needing treatment for specific health issues, but details are not specified.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: Granisetron
BNF-referencedGranisetron is a selective serotonin 5-HT3 receptor antagonist used primarily for the prevention and treatment of nausea and vomiting associated with cytotoxic chemotherapy and postoperative settings. It acts by blocking the 5-HT3 receptors located in the central nervous system and gastrointestinal tract, thereby inhibiting the emetic response. Granisetron is available in various forms including injectable solutions and tablets.
Indications
- Nausea and vomiting induced by cytotoxic chemotherapy
- Prevention of postoperative nausea and vomiting
Dosage
Children: For children aged 6 months to 17 years, refer to the BNF for Children for appropriate dosing guidelines, as individual dosage may vary based on age, weight, and specific treatment protocols.
Adults: For intravenous administration, the typical adult dose is 1 mg, given before the induction of anesthesia, diluted in 5 mL and administered over 30 seconds. For prevention of nausea and vomiting related to chemotherapy, it can be given for 3-5 days as needed.
Mechanism of action
Granisetron works by selectively blocking the 5-HT3 receptors, which are involved in the vomiting reflex. By antagonizing these receptors in both the central nervous system and the gastrointestinal tract, granisetron reduces the stimulation of the vomiting center, thus preventing nausea and vomiting.
Pharmacodynamics
Granisetron's pharmacodynamic effects are primarily based on its ability to inhibit the action of serotonin at the 5-HT3 receptor sites. This action reduces the incidence of nausea and vomiting, especially in patients undergoing chemotherapy or surgery. The onset of action is typically rapid, with significant effects observed within 30 minutes to 2 hours after administration.
Pharmacokinetics
Granisetron is well-absorbed when administered intravenously or orally. It exhibits a volume of distribution of approximately 4-5 L/kg and is primarily metabolized in the liver via cytochrome P450 enzymes. The elimination half-life ranges from 9 to 13 hours, allowing for once-daily dosing in many cases. Granisetron is primarily excreted in urine, with a small percentage excreted unchanged.
Adverse effects
- Extrapyramidal symptoms
- QT interval prolongation
- Serotonin syndrome
- Decreased appetite
- Dry mouth
- Flushing
- Generalized edema
- Vertigo
- Dystonia
Precautions
- Caution is advised in hepatic impairment
- Patients should avoid sun exposure to the patch site during use and for 10 days after removal
Pregnancy
Manufacturer advises to avoid use during pregnancy.
Breast-feeding
Avoid; no information available regarding safety during breastfeeding.
Storage
Store in a dry place, protected from light. Keep out of reach of children.
Formulations
- {'formulation': 'Powder for solution for infusion', 'strength': '1 mg per 1 ml', 'pack_size': '10 ampoules'}
- {'formulation': 'Granisetron 3 mg/3 ml concentrate for solution for injection', 'pack_size': '10 ampoules'}
- {'formulation': 'Granisetron 1 mg tablets', 'pack_size': '10 tablets'}
- {'formulation': 'Granisetron 2 mg tablets', 'pack_size': '10 tablets'}
- {'formulation': 'Transdermal patch', 'strength': '3.1 mg per 24 hours', 'pack_size': '1 patch'}
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Clinical monograph: hyrochloride
Hydrochloride refers to the hydrochloride salt form of a drug, commonly used to enhance its solubility and stability. This form is prevalent in various medications, including antihistamines, antidepressants, and other therapeutic agents.
Dosage
Children: Refer to the specific drug's prescribing information for detailed dosage.
Adults: Refer to the specific drug's prescribing information for detailed dosage.
Mechanism of action
The mechanism of action varies depending on the specific drug that is in hydrochloride form. Generally, hydrochloride salts dissociate in solution to release the active drug, which then interacts with specific receptors or enzymes in the body to exert its pharmacological effects.
Pharmacodynamics
Pharmacodynamics will depend on the specific active ingredient in the hydrochloride formulation. Typically, the pharmacodynamics involve the interaction of the drug with its target receptors, leading to a physiological response. This can include altering neurotransmitter levels, inhibiting enzymes, or blocking receptors, among other actions.
Pharmacokinetics
Pharmacokinetics will also vary based on the specific drug. Generally, hydrochloride salts are well absorbed after oral administration, with peak plasma concentrations occurring within a few hours. They may undergo first-pass metabolism in the liver, and their elimination half-life can vary widely depending on the drug's characteristics.
Pregnancy
Consult with healthcare provider before use; risk versus benefit should be evaluated.
Breast-feeding
Use with caution; monitor for potential adverse effects in the infant.
Storage
Store in a cool, dry place away from light; keep out of reach of children.
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Molecular reference: Granisetron
PubChem CID 5284566Molecular formula: C18H24N4O
Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.
This drug in other countries
The same active ingredient registered across other registries we cover - including different brands.
- ASCORIL-D · Glenmark Pharmaceuticals
- GRANISETRON CONCENTRATE FOR SOLUTION FOR INJECTION · Tasa Pharma
- KYTRIL · Atnahs Pharma
- KYTRIL · Imperial Managed Solutions
- KYTRIL 1MG INJECTION · Imperial Managed Solutions
- SETONIX SOLUTION FOR INJECTION. · Evka Consultz
- ADCO GRANISETRON 1 mg/1 ml
- ADCO GRANISETRON 3 mg/3 ml
- GRANITRIL 1 mg TABLETS
- GRANITRIL INJECTION
- GRANTRYL 3 mg/3 ml
- GRANTYL 1 mg/1 ml